The Long Run Podcast

In two thousand seven we finally had a break through. This is a collaboration with brion cubunca's lab at stanford. Bryan really knows, you know, bata to a generic receptor. And so we wanted to apply it g pc rs and structure base drug discovery. We developed a s one p one receptor agonist that became the foundation of the company. That molecule is now on the markets called zyposia,. It's treating patients with both m s and i b d. The journey, again, was sort of fascinating. Find out why, go to timberman report dot com and click subscribe.